Feasibility and safety of sorafenib treatment in hepatocellular carcinoma patients with spontaneous rupture

Table 1 Clinical characteristics of the 32 patients with ruptured hepatocellular carcinoma n (%)

Variable	Total (n = 32)
Age
Mean (range), yr	53 (39-71)
Gender (male/female)	25/7
Etiology
HBV/HCV/alcohol/others	25 (78.1)/2 (6.3)/2 (6.3)/3 (9.4)
Child-Pugh classification
A/B/C	3 (9.4)/12 (37.5)/10 (31.3)
Extra-liver sites of metastatic disease	4 (12.5)
Tumor size (cm)	8.3 (2.9-25.5)
Tumor number
Single/multiple	8 (25.0)/24 (75.0)
Within Milan criteria	3 (9.4)
BCLC stage
0/A/B/C/D	0 (0.0)/3 (9.4)/11 (34.4)/ 12 (37.5)/6 (18.8)
Alpha-fetoprotein (ng/mL)
mean (range)	864 (6-54000)
Treatment Resection/TAE(TACE)	22 (68.8)/10 (31.2)
Sorafenib	12 (37.5)

HBV: Hepatitis B virus; HCV: Hepatitis C virus; BCLC: Barcelona Clinical Liver Cancer; TAE: Transarterial embolization; TACE: Transarterial chemoembolization.

Table 2 Sorafenib toxicity grades based on common terminology criteria for adverse events version 4.0

Adverse events	Grade 1/2	Grade 3/4
Hand-foot skin reaction	3	1
Diarrhea	2	2
Hypertension	1	0
Skin rash	2	0
Anorexia	2	0
Mucositis	1	0
Agrypnia	1	0